Corbus announces first patient dosed in Phase 1 CRB-913 study
Corbus Pharmaceuticals (CRBP) announced the dosing of the first subject in the single ascending dose / multiple ascending dose portion of the ...
Open Access Government4d
AI-driven innovations in GPCR ligand synthesis for treating inflammatory diseases
G Protein-Coupled Receptors (GPCRs) in advancing GPCR-targeted therapies, including the use of agonists, antagonists, biased ...
Shattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class ...
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel ...
Namibian Sun on MSN6d
Scientists discover new breakthrough in weight loss and diabetes treatment
Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...